









© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases 
Society of America. 
This is an Open Access article distributed under the terms of the Creative Commons 
Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits 
unrestricted reuse, distribution, and reproduction in any medium, provided the original work 
is properly cited. 
Pathogens associated with linear growth faltering in children with diarrhea and impact of 
antibiotic treatment: The Global Enteric Multicenter Study 
 
Dilruba Nasrin, Ph.D.,a,c* William C. Blackwelder, Ph.D.,a,c Halvor Sommerfelt, Ph.D.,d Yukun Wu, 
Ph.D.,a,c Tamer H Farag, Ph.D.,a,c Sandra Panchalingam, Ph.D.,a,c Kousick Biswas, Ph.D.,e Debasish 
Saha, M.S.,f M Jahangir Hossain, M.B.B.S.,f Samba O Sow, M.D.,g Robert F Breiman, M.D.,h Dipika Sur, 
M.D.,i Abu S G Faruque, M.D.,j Anita K M Zaidi, M.B.B.S.,k Doh Sanogo, M.D.,g Boubou Tamboura, 
Pharm.D.,g Uma Onwuchekwa, M.S.,g Byomkesh Manna, Ph.D.,i Thandavarayan Ramamurthy, Ph.D.,i 
Suman Kanungo, Ph.D.,i Richard Omore, Ph.D.,l John B Ochieng, Ph.D.,l Joseph O Oundo, Ph.D.,l 
Sumon K Das, M.B.B.S.,j Shahnawaz Ahmed, M.B.B.S.,j Shahida Qureshi, M.Sc.,k Farheen Quadri, 
M.B.B.S.,k Richard A Adegbola, Ph.D.,f, Martin Antonio, Ph.D.,f Inacio Mandomando, B.S.,m,n Tacilta 
Nhampossa, M.D.,m,n Quique Bassat,m,n,o .Anna Roose,a,c  Ciara E O’Reilly, Ph.D.,p Eric D Mintz, M.D.,p  
Usha Ramakrishnan.,q Helen Powell, Ph.D.,a,c Yuanyuan Liang.,r James P Nataro, M.D.,a,b,c Myron M 
Levine, M.D.a,b,c and Karen L Kotloff, M.D.,a,b,c. 
 
a,b,c- Center for Vaccine Development and Global Health,a Department of Pediatricsb and 
Medicine,c University of Maryland School of Medicine, Baltimore, MD, USA. 
     d- Centre for Intervention Science in Maternal and Child health (CISMAC) and Centre for 
International Health, University of Bergen, Bergen, and Cluster for Global Health,    Division for 
Health Services, Norwegian Institute of Public Health, Oslo, Norway. 
e- Department of Veterans Affairs, Cooperative Studies Program Coordinating Center, Perry 






/jid/advance-article/doi/10.1093/infdis/jiab434/6371002 by London School of H
ygiene & Tropical M














f- Medical Research Council Unit The Gambia at London School of Hygiene and Tropical 
Medicine, Fajara, The Gambia. 
g- Centre pour le Développement des Vaccins, Bamako, Mali.  
h- Global Disease Detection Division, Kenya Office of the US Centers for Disease Control and 
Prevention, Nairobi, Kenya. 
i- National Institute of Cholera and Enteric Diseases, Kolkata, India. 
j- International Centre for Diarrhoeal Disease Research, Mohakhali, Dhaka, Bangladesh. 
k- Department of Paediatrics and Child Health, the Aga Khan University, Karachi, Pakistan. 
l- Kenya Medical Research Institute/Center for Global Health Research  (KEMRI-CGHR), Kisumu, 
Kenya. 
m- Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique. 
n- ICREA, Pg. Lluís Companys 23, 08010 Barcelona, Spain. 
o- ISGlobal, Hospital Clínic - Universitat de Barcelona, Barcelona, Spain 
p- Division of Foodborne, Waterborne, and Environmental Diseases, US Centers for Disease 
Control and Prevention, Atlanta, GA, USA. 
q- Hubert Department of Global Health, Rollins School of Public Health, Emory University, 
Atlanta, Georgia, USA.  
r- Department of Epidemiology and public health, University of Maryland School of Medicine, 







/jid/advance-article/doi/10.1093/infdis/jiab434/6371002 by London School of H
ygiene & Tropical M















Karen L. Kotloff, MD 
Center for Vaccine Development and Global Health 
University of Maryland School of Medicine 
685 W. Baltimore Street, HSF 480 
Baltimore, Maryland, 21201  USA 
kkotloff@medicine.umaryland.edu 
Tel:  410-706-6541 
Fax: 410-706-6205 
 
Secondary corresponding author: 
Dilruba Nasrin, Ph.D 
Center for Vaccine Development and Global Health 
University of Maryland School of Medicine 
685 W. Baltimore Street, HSF 480 
Baltimore, Maryland, 21201  USA 
dnasrin@som.umaryland.edu 







/jid/advance-article/doi/10.1093/infdis/jiab434/6371002 by London School of H
ygiene & Tropical M















Background The association between childhood diarrheal disease and linear growth faltering in 
developing countries is well-described. However, the impact attributed to specific pathogens has not 
been elucidated, nor has the impact of recommended antibiotic treatment.  
Methods The Global Enteric Multicenter Study (GEMS) enrolled children seeking healthcare with 
moderate-to-severe diarrhea (MSD) at seven sites in sub-Saharan Africa and South Asia. At 
enrollment, we collected stool samples to identify enteropathogens. Length/height was measured at 
enrollment and follow-up, ~60 days later, to calculate change in length/height for age Z scores 
(ΔHAZ). The association of pathogens with ΔHAZ was tested by linear mixed effects regression 
models. 
Results Among 8,077 MSD cases analyzed, the proportion with stunting (HAZ<-1) increased from 
59% at enrollment to 65% at follow-up (p<.0001). Pathogens significantly associated with linear 
growth decline were Cryptosporidium (p<0.001), typical enteropathogenic Escherichia coli (p=0.013), 
and untreated Shigella (p=0.009) among infants (0-11 months), and enterotoxigenic E. coli encoding 
heat stable toxin (p<0.001) and Cryptosporidium (p=0.03) among toddlers (12-23 months). Shigella-
infected toddlers given antibiotics had improved linear growth (p=0.02). 
Conclusion Linear growth faltering among children aged 0-23 months with MSD is associated with 
specific pathogens and can be mitigated with targeted treatment strategies, as demonstrated for 
Shigella.    
Keywords: Diarrhea, pathogens, growth faltering, stunting, children, antibiotics 
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Diarrheal disease is associated with linear growth faltering among young children [1]. Community-
based studies in low-resource settings demonstrate an increasing risk of stunting at age 24 months 
with each diarrheal episode and each day of diarrhea before that age [2]. In turn, stunting is a risk 
factor for poor health and development [3]. Even mild stunting predicts an increased risk of death 
during the first two years of life [4].  
Although most acute diarrhea is caused by infection, few studies have elucidated the impact of 
specific pathogens on growth, and a limited array of pathogens has been examined [5-8]. Moreover, 
trials designed to evaluate the efficacy of pathogen-specific treatment have used short-term clinical 
and bacteriologic cure as endpoints [9, 10], while the impact on growth has not been characterized. 
The Global Enteric Multicenter Study (GEMS) is a prospective, matched case-control study of the 
burden, etiology, and adverse clinical outcomes of moderate-to-severe diarrhea (MSD) in children 
aged 0-59 months in sub-Saharan Africa and South Asia. GEMS found an association between MSD 
and linear growth faltering [11, 12]. In this paper, we assessed pathogen-specific associations and 
whether antibiotic treatment of Shigella dysentery, according to World Health Organization (WHO) 
recommendations, improved growth outcomes.  
MATERIALS AND METHODS 
Study design and participants 
For 36 months at each site, children aged 0-59 months were enrolled into GEMS at sites in Basse 
(The Gambia), Bamako (Mali), Manhiça (Mozambique), Siaya County (Kenya), Kolkata (India), 
Mirzapur (Bangladesh), and Karachi, Bin Qasim town (Pakistan) according to published methods [13-
15]. To be eligible for enrollment, a child had to reside in the site’s demographic surveillance area, 
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hours) that began in the previous 7 days, and meet at least one of the following criteria for MSD: 
sunken eyes, decreased skin turgor, visible blood in stool, or a clinician recommendation for 
intravenous rehydration or hospitalization. We aimed to enroll ~220 eligible children per site per 
year into each of three age groups: infants 0-11 months, toddlers 12-23 months, and young children 
24-59 months. Cases were eligible for re-enrollment if they developed a new episode of MSD after 
their 60-day follow-up visit [13]. For this paper, only children with MSD were included.   
Data collection 
During the enrollment visit at the health center, all children underwent a standardized clinical 
assessment, anthropometric measurements, and provided a stool sample to identify 
enteropathogens [13, 15]. Stool collection, transport, and pathogen identification methods have 
been described [16]. Management of diarrhea at the health center, including antibiotic use, was 
documented. Approximately 60 days after enrollment (49-91 days), participants were visited at 
home to assess vital status and repeat anthropometric measurements.  
Anthropometric measurements 
We measured standing height for children >2 years old, and recumbent length for younger children 
and those unable to stand unassisted, thrice to the nearest 0.1 cm using a “Shorr board,” following a 
two-person standardized measurement procedure [17]. The median of the three measurements was 
used to calculate the length/height-for-age Z score (HAZ) [18, 19].  
Before study initiation, staff at each site underwent anthropometry training followed by a 
standardization exercise to calculate intra-rater and inter-rater (trainee versus instructor) variability 
[13]. Trainees who exceeded the acceptable measurement error (0.5 cm) at least half the time did 
not undertake field activities until retrained and deemed competent. A proficient member of each 






/jid/advance-article/doi/10.1093/infdis/jiab434/6371002 by London School of H
ygiene & Tropical M














training for existing staff every 4-6 months. The core team visited each site approximately twice 
annually to train, observe field activities, and review standardization results. 
The study was approved by ethics committees at the University of Maryland, Baltimore, and each 
field site. Informed consent was obtained from the parent or guardian of each child prior to 
performing study procedures. 
Statistical methods 
Variable definitions 
Age was measured on a continuous scale and analysis were stratified by age group. The HAZ was 
calculated at enrollment and follow-up using the median of the three length/height measurements and 
age, according to WHO standards [19]. We defined stunting as HAZ < -1 and degree of stunting, as 
mild (-2 <HAZ < -1), moderate (-3 < HAZ < -2), or severe (HAZ < -3), at enrollment and follow-up.  
Data analysis 
This analysis included MSD cases with both enrollment and follow-up measurements; implausible or 
inconsistent measurements between enrollment and follow-up were excluded (Supplemental Figure 
S1).  
The primary outcome is change in linear growth (HAZ), which was calculated for each child as the 
difference in HAZ from enrollment to follow-up. A negative change in linear growth is deemed 
growth faltering. We initially compared enrollment and follow-up HAZ within each age group (and 
study site) using a one sample t-test for HAZ and adjusted for individuals with multiple episodes of 
MSD during the study period (SAS proc surveymeans t with CLUSTER statement). We compared 
presence of stunting and degree of stunting at enrollment and follow-up using a Wilcoxon signed-
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Pathogens were tested for association with change in linear growth within each age group. We 
limited the analysis to pathogens that were 1) significantly associated with MSD in at least four sites 
[12] and/or 2) associated with increased risk of dying in a pooled analysis of cases at all sites [12]. 
For the first criterion, we included rotavirus, Cryptosporidium, Shigella, and enterotoxigenic 
Escherichia coli encoding heat stable toxin with or without targets for heat labile enterotoxin (ST-
ETEC) for all age groups, and adenovirus serotypes 40 and 41 for the two youngest groups. For the 
second criterion, we additionally included typical enteropathogenic E. coli (tEPEC) in the analyses 
involving infants [12]. We used a linear mixed effects regression model to examine the association of 
each of the above-named pathogens individually with change in linear growth among MSD cases by 
age group. In addition to the pathogen, the model also included HAZ at enrollment, age at 
enrollment in months, duration to follow-up in days, and study site. Treatment of Shigella with a 
WHO-recommended antibiotic (ciprofloxacin, third-generation cephalosporins, azithromycin, 
pivmecillinam) [20] could modify any potential association of Shigella with linear growth. We 
therefore examined the need for an interaction term between the presence and absence of Shigella 
with or without antibiotic treatment. The interaction term was retained if the associated p-value was 
< 0.10. Pathogens associated (p-value < 0.10) with HAZ in the individual models were combined 
into a single age stratified model, which included the same confounding variables described 
previously for the individual models. Unless otherwise stated, a p-value < 0.05 was considered 
statistically significant. SAS version 9.4 (SAS Institute, Cary, NC) was used for all summary statistics 
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Between December 1, 2007 and March 3, 2011, 8,077 MSD episodes occurring among 7,545 children 
were analyzed: 3,408 were ages 0-11 months, 2,741 were12-23 months, and 1,928 were 24-59 
months. There were 1,362 episodes excluded from analysis due to missing measurements (63.2%), 
implausible values (17.8%), death before follow-up (14.0%), and follow-up visit outside the 
acceptable time window (5.0%) (Supplemental Figure S1). Children with excluded and included 
episodes had similar demographic features (Supplemental Table S1), except those excluded because 
of death had significantly lower enrollment HAZ scores compared to included children in 14 of 21 
comparisons (3 age groups at 7 sites).   
Mean enrollment HAZ in each age group, at every site, was below zero and became more negative 
with increasing age (Supplemental Table S2), as did the proportion with stunting at enrollment 
(Table 1). A total of 58.7% of cases were stunted at enrollment (32.2% mild, 18.0% moderate, 8.5% 
severe).  
The proportion of cases with stunting was significantly higher at follow-up than enrollment in every 
age group (Table 1, Supplemental Table S2), with a difference of 9.2% in infants, 5.8% in toddlers, 
1.5% in young children. A total of 64.9% of cases were stunted at follow-up (33.3% mild, 20.6% 
moderate, 11.0% severe).  
Pathogens associated with linear growth faltering 
In the individual pathogen analyses for infants, the presence of Cryptosporidium or tEPEC was 
significantly associated with a greater decline in linear growth compared to those without either 
pathogen (difference in ΔHAZ for Cryptosporidium -0.09, 95% CI -0.14 and -0.04, p<0.001; and for 
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and WHO-prescribed antibiotics was statistically significant (p = 0.012). Shigella episodes not treated 
with antibiotics resulted in a greater decline in linear growth compared to treated episodes 
(difference in ΔHAZ -0.16, 95% CI -0.29, -0.03, p=0.017) while Shigella episodes treated with 
antibiotics were not associated with positive or negative linear growth. These three pathogens, 
including the interaction term, were included in a final fully adjusted model. Rotavirus and ST-ETEC 
were not associated with linear growth faltering among infants.  
Amongst toddlers, Cryptosporidium was associated with a greater decline in linear growth compared 
to those without Cryptosporidium (difference in ΔHAZ -0.05, 95% CI -0.09, -0.003, p=0.038, Table 2), 
with the difference in ΔHAZ very similar to infants. The presence of rotavirus or ST-ETEC also 
resulted in a greater decline in linear growth (difference in ΔHAZ for rotavirus -0.04, 95% CI -0.07, -
0.002, p=0.063 and for ST-ETEC -0.12, 95% CI -0.17, -0.06, p <0.001, respectively). The result for 
rotavirus was not statistically significant but met our criteria for inclusion in the final adjusted model. 
The interaction term between Shigella and antibiotic treatment was significant (p-value 0.003), and 
antibiotic treatment improved linear growth in toddlers with shigella (difference in ΔHAZ 0.07, 95% 
CI 0.01, 0.13, p=0.019). Shigella not treated with antibiotics resulted in further declines in linear 
growth (difference in ΔHAZ -0.06, 95% CI -0.12, 0.006, p=0.08). Adenovirus 40/41 was not associated 
with linear growth among MSD cases aged 12-23 months. Each of Cryptosporidium, rotavirus, ST-
ETEC, and the interaction between Shigella and antibiotic treatment were included in a final model; 
however, rotavirus was subsequently excluded from the final model as the p-value was not 
statistically significant. For those pathogens remaining in the final model, the results of this 
pathogen adjusted analysis were very similar to those of the individual pathogen analyses (Table 2).  
None of the individual pathogens were associated with linear growth faltering in the oldest age 
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Antibiotic prescribing practices and susceptibility patterns  
In an ad hoc analysis, we further explored the observed association between linear growth faltering 
and failure to treat Shigella with antibiotics recommended by WHO for dysentery. For context, we 
first examined antibiotic prescribing practices for Shigella dysentery (Figure 1 and Supplemental 
Table S3) and the susceptibility patterns of offending strains. 
A total of 2,026 of all MSD episodes (25·1%) had dysentery; 1,894 (93.5%, range 79.9% [Pakistan] to 
99.6% [Bangladesh]) were prescribed antibiotics. The most common antibiotics were ciprofloxacin, 
trimethoprim/sulfamethoxazole, and metronidazole (59·9%, 22·6%, and 11·6%, respectively). A 
WHO-recommended antibiotic was prescribed for 1,272 dysentery episodes (62.8%) and for 583 
shigella-positive dysentery episodes (79.8%) (Figure 1, Supplemental Table S3).  
There was considerable regional diversity in antibiotic prescribing practices. A WHO-recommended 
antibiotic was prescribed for 614 of the 621 Shigella dysentery episodes in Asia (98.9%), but for only 
20 of the 110 episodes at the four African sites (18.1%). Ciprofloxacin was the most prescribed 
antibiotic at the Asian sites, including India (77.8%), Bangladesh (86.5%), and Pakistan (78.9%), but 
was a rare choice in Africa. At the African sites, the most commonly prescribed antibiotic was 
trimethoprim-sulfamethoxazole in The Gambia (60.0%), Mali (60.0%), and Kenya (40.5%), and 
nalidixic acid in Mozambique (87·5%). 
Virtually all (>99%) Shigella strains were susceptible to ciprofloxacin in The Gambia, Mali, 
Mozambique, Kenya, and Pakistan, compared to 87.0% in Bangladesh and only 35.4% in India.  At the 
African sites, >80% of Shigella isolates were resistant to trimethoprim/sulfamethoxazole, while 85% 
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Impact of antibacterial treatment of shigellosis on linear growth  
 Shigella was cultured in 731 of the dysentery episodes (36.1%) and 270 watery diarrhea episodes 
(4.5%) (Figure 1). A WHO-recommended antibiotic was prescribed for 583 shigella-positive dysentery 
episodes (79.8%) compared to 71.(26.3%) shigella-positive watery diarrhea episodes (Figure 1). 
Analysis of the impact of antibiotic treatment of shigellosis on linear growth was performed 
separately for shigella-positive watery diarrhea and dysentery (Table 3). 
In toddlers, whose incidence of Shigella-positive MSD was almost double that of the other two age 
groups [12], a ~4-fold reduction in linear growth faltering was observed among Shigella-positive 
dysentery cases treated with WHO-recommended antibiotics compared to untreated children (ΔHAZ 
-0.10, 95% CI -0.18, 0.03 versus ΔHAZ -0.37, 95% CI -0.48, -0.26, p=0.03). A similar trend was 
observed among infants with Shigella-positive dysentery and toddlers with Shigella-positive watery 
diarrhea, but the differences did not reach statistical significance with the small sample sizes (Table 
3).  
To address whether antibiotics exert a nonspecific growth-promoting effect on children with 
diarrhea, we compared ΔHAZ among MSD cases with rotavirus (n=1,493) or Cryptosporidium (n=945) 
who were offered either ciprofloxacin, third-generation cephalosporins, azithromycin, or 
pivmecillinam with those not offered these antibiotics. Overall, 33.0% of rotavirus-positive cases and 
32.0% of Cryptosporidium-positive cases received one of these antibiotics, but no significant 
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We previously demonstrated that among children 0-59 months of age living in low-resource settings 
in South Asia and sub-Saharan Africa, an episode of MSD was associated with an increased risk of 
stunting over the ensuing 2-3 months. Now we present findings involving a broad array of pathogens 
indicating that four pathogens (Cryptosporidium, tEPEC, Shigella, and ST-ETEC) exert the largest 
negative effect on linear growth among infants and toddlers. We found that the risk associated with 
Shigella was largely limited to episodes not treated with WHO-recommended antibiotics.  
To our knowledge, this is the first study to demonstrate that antibiotic treatment of dysentery 
according to WHO guidelines significantly ameliorates the linear growth impairment associated with 
Shigella infection, and in toddlers also augments growth. Previous clinical trials of children with 
shigellosis examined the short-term benefits of antibiotics (resolution of diarrheal disease symptoms 
and fecal shedding) but did not evaluate the impact on linear growth faltering, widely believed to be 
a proxy for mortality and poor health outcomes in the longer term. We observed a statistically 
significant improvement in linear growth among children with Shigella-positive dysentery in the 12-
23 month age group, and a similar trend among infants with Shigella-positive dysentery and toddlers 
with Shigella-positive watery diarrh a that did not reach statistical significance.  Regional differences 
in executing WHO guidelines were apparent. Although most Asian sites administered the 
recommended first line therapy with ciprofloxacin, 20% of episodes were missed and escalating 
prevalence of ciprofloxacin resistance threatens the efficacy of recommended treatment, 
particularly in India. The African sites provided treatment to only 20% of Shigella-positive dysentery 
episodes but in most cases Shigella was resistant to the antibiotic chosen 
(trimethoprim/sulfamethoxazole). The prevalence of resistance to trimethoprim/sulfamethoxazole 
precludes its routine use unless supported by local susceptibility patterns.   
Our findings corroborate and expand results of studies in Peru [6] and Guinea Bissau [7], which  
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We previously reported this risk period extends to include the second year of life, when 
Cryptosporidium was strongly associated with MSD at all GEMS sites, regardless of HIV prevalence 
[12] and was associated with death during the ~60 days following an MSD episode in toddlers. Our 
current findings suggest the impact of Cryptosporidium on mortality may be linked to its 
considerable nutritional insult, as measured by a negative ΔHAZ. Strategies for point-of-care 
diagnosis and identification of appropriate therapeutic agents for case management of 
cryptosporidiosis in low-resource settings are needed and should be evaluated for their impact on 
growth, and if possible, survival. 
Our findings also demonstrate an association between ST-ETEC diarrhea and linear growth faltering 
during the second year of life. Previous studies of the relationship between ST-ETEC and stunting 
have conflicting results. One study of children aged 3-48 months in rural Bangladesh demonstrated a 
significant association between the percentage of days with ETEC diarrhea during 60-day intervals 
and failure to gain weight but not with impeded linear growth [5]. Another study involving a birth 
cohort followed for two years in urban Bangladesh found that stunted or undernourished children 
aged 12-24 months were significantly more likely to have experienced ETEC diarrhea than those who 
were not stunted [21]. Our analysis differs from previous studies in that it distinguishes ST-ETEC 
from the less virulent ETEC pathotype encoding only LT, and we limited enrollment to clinically more 
severe forms of diarrheal illness. In addition, we examined linear growth over a relevant time frame 
(2-3 months after MSD onset) and demonstrated ST-ETEC’s impact relative to other pathogens that 
were significantly associated with MSD. Nonetheless, the observed effect of infection on linear 
growth was somewhat unexpected since ETEC is often considered a self-limited secretory diarrhea 
that in animal models [22] and human challenge studies caused little or no inflammation or 
alteration of intestinal integrity that might interfere with growth [23, 24]. Other data, however, 
suggest ST-ETEC can elicit an inflammatory response involving IL-8 expression [25, 26]. Peruvian 
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Several limitations of this study could not be addressed in the case-control analysis. First, 
unmeasured events between enrollment and follow-up may have influenced growth, so it is notable 
that MSD cases grew significantly less during follow-up than their matched controls, despite having 
comparable HAZ at enrollment [12]. Second is that the detrimental effects of growth faltering 
following MSD can be overcome by catch-up growth. Even if that were the case, the 2-3 months 
after MSD onset were a particularly vulnerable period when mortality rates among cases were 8·5-
fold higher than among matched controls [12]. We recognize that observational studies are 
suboptimal for evaluating the impact of antibiotics against Shigella-associated linear growth 
faltering; however, the inclusion of objective endpoints (height/length, pre-defined diarrhea and 
dysentery, and fecal microbiology) mitigate these concerns. Finally, we used directly observed 
inpatient administration of antibiotics and/or prescription of antibiotics as a proxy for antibiotic use 
and were unable to measure compliance. 
In conclusion, our findings suggest prevention or treatment of infection with four pathogens 
(Cryptosporidium, ST-ETEC, tEPEC, and Shigella) may reduce the burden of linear growth faltering in 
children. The adverse effects of Shigella were mitigated by administration of WHO-recommended 
antibiotics; however, these antibiotics were prescribed in only 63% of dysentery episodes and in 
several sites antibiotic practices did not match local susceptibility patterns. Increasing resistance of 
Shigella to antibiotics globally could leave few options for effective therapy[28]. Accordingly, WHO 
has declared antibiotic-resistant Shigella to be a serious threat[29]. It seems prudent that for benefit 
to exceed risk, treatment of shigellosis should be judicious, guided by susceptibility data when 
possible, and directed toward individuals at risk for severe disease or complications. Because 
stunting is prevalent worldwide and directly associated with poor outcomes, interventions with a 
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TABLES FOR MAIN BODY OF PAPER 
Table 1. Degree of stunting in cases with moderate-to-severe diarrhea at enrollment and at 
~60-day follow-up visit, by age group 
Degree of stunting at 
enrollment, by age (No. 
(%)) 
Degree of stunting at follow-up, by age (No. (%)) 
None Mild Moderate Severe 
0-11 months (n=3,408) 1,414 (41·5) 1,093 (32·1) 616 (18·1) 285 (8·3) 
None  
 1,727 (50.7) 
1302 (75.4) 391 (22.6) 32 (1.9) 2 (0.1) 
Mild  
1,049 (30.8) 
104 (9.9) 640 (61.0) 291 (27.7) 14 (1.3) 
Moderate  
435 (12.7) 
8 (1.8) 57 (13.1) 257 (59.1) 113 (26.0) 
Severe  
197 (5.8) 
0 (0) 5 (2.5) 36 (18.3) 156 (79.2) 
12-23 months 
(n=2,741) 
838 (30.6) 951 (34·7) 591 (21·6) 361 (13·2) 
None  
998 (36.4) 774 (77.6) 222 (22·2) 2 (0.2) 0 
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556 (20.3) 1 (0.2) 74 (13·3) 374 (67·3) 107 (19·2) 
Severe  
276 (10.1) 0 1 (0.4) 24 (8.7) 251 (90.9) 
24-59 months (n-1,928) 582 (30.2) 647 (33·6) 457 (23·7) 242 (12·6) 
None  
612 (31.7) 528 (86·3) 84 (13·7) 0 0 
Mild  
642 (33.3) 54 (8·4) 509 (79·3) 79 (12·3) 0 
Moderate  
462 (24.0) 0 54 (11·7) 358 (77·5) 50 (10.8) 
Severe 
212 (11.0) 0 0 20 (9·4) 192 (90.6) 
 
Degree of stunting was significantly higher at follow-up in each age group: p<0.0001 for the 0-11 and 
12-23 month groups and p=0.0001 for the 24-59 month group, by Wilcoxon signed-rank test on the 
difference (follow-up minus enrollment) in stunting score: 0=none (HAZ >-1), 1=mild (<-1 HAZ >-2), 
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Table 2: Change in linear growth (ΔHAZ) between enrollment and follow-up  from individual and multiple pathogen models among 
children from seven GEMS sites, by age group.   
 
No. (%) of 
episodes with 
pathogen  
Individual pathogen model* Multiple pathogen model□ 
Difference in ΔHAZ 
(95% CI) 
p-value 
Difference in ΔHAZ (95% 
CI) 
p-value 
0-11 months (n=3,408) 
Cryptosporidium 525 (15.4) -0.09 (-0.14, -0.04) <0.001 -0.09 (-0.14, -0.04)  <0.001 
Shigella, not treated with antibiotic 72 (2.1) -0.16 (-0.29, -0.03)  0.017 -0.17 (-0.31, -0.04)  0.009 
Shigella, treated with antibiotic 93 (2.7) 0.05 (-0.07, 0.17)  0.38 0.05 (-0.07, 0.17) 0.41 
Typical EPEC 304 (8.9) -0.08 (-0.15, -0.02)  0.012 -0.08 (-0.15, -0.02) 0.013 
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ST-ETEC 203 (6.0) 0.006 (-0.07, 0.08)  0.89   
Adenovirus 40/41 104 (3.0) -0.06 (-0.17, 0.05)  0.27   
12-23 months (n=2,741) 
Cryptosporidium 312 (11.4) -0.05 (-0.09, -0.003)  0.038 -0.05 (-0.09, -0.005) 0.029 
Shigella, not treated with antibiotic 159 (5.8) -0.06 (-0.12, 0.006)  0.08 -0.06 (-0.12, 0.001)  0.054 
Shigella, treated with antibiotic 282 (10.3) 0.07 (0.01, 0.13)  0.019 0.06 (0.009, 0.13)  0.024 
Rotavirus 492 (18.0) -0.04 (-0.07, 0.002)  0.063   
ST- ETEC 199 (7.3) -0.12 (-0.17, -0.06)  <0.001 -0.12 (-0.17, -0.06)  <0.001 
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Table 3. Linear growth following an episode of Shigella-positive dysentery and watery diarrhea, 
according to whether WHO-recommended treatment was prescribed*, by age group 
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Assessed using linear regression, controlling for age, site, enrollment HAZ, and days until follow-up visit. 
* Prescription of a WHO-recommended antibiotic for dysentery (either ciprofloxacin, third 
generation cephalosporin, azithromycin, or pivmecillinam).  








-0.21 -0.47 -0.10 -0.37 -0.12 -0.14 
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Figure 1. Distribution of diarrhea episodes included in the analysis according to the presence of dysentery, 
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